This page has only limited features, please log in for full access.

Unclaimed
Anna Borrelli
A.U.O. “San Giovanni di Dio e Ruggi d’Aragona”, 84121 Salerno, Italy

Basic Info

Basic Info is private.

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Journal article
Published: 07 June 2021 in Vaccines
Reads 0
Downloads 0

The objectives of this study were to evaluate the psychological factors of health perception, mistrust, anxiety, fear, and indecision of Italians vaccinated against COVID-19, and conduct an analysis of the relationships between these factors and other variables: sex, vaccine priority ministerial categories, and the type and dose of vaccine. The participants included 1564 subjects who joined the vaccination campaign at the COVID-19 Vaccination Center in Salerno, Italy. A survey was conducted in the reference period March–April 2021 using a brief anamnestic questionnaire. In addition, the following standardized scales were used: the State–Trait Anxiety Inventory (STAI-Y) and the Short Form Health Survey (SF-12). The results showed that, in terms of the type of vaccine received, the interviewees felt more confident in having received the Comirnaty (Pfizer-BioNTech, 23.5%) and Vaxzevria (AstraZeneca, 18.6%) vaccines—feeling less tense (2.1%; Vaxzevria (AstraZeneca) = 3.2%), frightened (1%; Vaxzevria (AstraZeneca) = 1.4%), not at all nervous (61.1%; Vaxzevria (AstraZeneca), 43.6%), and not at all/undecided (67.9%; Vaxzevria (AstraZeneca), 58.6%). Regarding the mood and psychological states considered at the different vaccine administration times, other important differences emerged as the interviewees reported higher levels of tension, nervousness, and fear during the first phase of vaccine administration. Specifically, 40.7% (second dose, 32.7%) felt somewhat tense at the first dose, 26.4% felt frightened (second dose, 21.8%), and 33.8% felt nervous (second dose, 26.8%). The perceived state of health also increased at the end of the vaccination cycle, as, at the second dose, 15.4% of the sample reported an evaluation of “excellent” (first dose, 12.4%).

ACS Style

Giuseppina Moccia; Luna Carpinelli; Giulia Savarese; Anna Borrelli; Giovanni Boccia; Oriana Motta; Mario Capunzo; Francesco De Caro. Perception of Health, Mistrust, Anxiety, and Indecision in a Group of Italians Vaccinated against COVID-19. Vaccines 2021, 9, 612 .

AMA Style

Giuseppina Moccia, Luna Carpinelli, Giulia Savarese, Anna Borrelli, Giovanni Boccia, Oriana Motta, Mario Capunzo, Francesco De Caro. Perception of Health, Mistrust, Anxiety, and Indecision in a Group of Italians Vaccinated against COVID-19. Vaccines. 2021; 9 (6):612.

Chicago/Turabian Style

Giuseppina Moccia; Luna Carpinelli; Giulia Savarese; Anna Borrelli; Giovanni Boccia; Oriana Motta; Mario Capunzo; Francesco De Caro. 2021. "Perception of Health, Mistrust, Anxiety, and Indecision in a Group of Italians Vaccinated against COVID-19." Vaccines 9, no. 6: 612.

Journal article
Published: 12 March 2021 in Antioxidants
Reads 0
Downloads 0

Background: Arterial hypertension is the most important risk factor for cardiovascular diseases, myocardial infarction, heart failure, renal failure and peripheral vascular disease. In the last decade, milk-derived bioactive peptides have attracted attention for their beneficial cardiovascular properties. Methods: Here, we combined in vitro chemical assay such as LC-MS/MS analysis of buffalo ice cream, ex vivo vascular studies evaluating endothelial and smooth muscle responses using pressure myograph, and translational assay testing in vivo the vascular actions of PG1 administration in murine models. Results: We demonstrate that a novel buffalo ice-cream-derived pentapeptide “QKEPM”, namely PG1, is a stable peptide that can be obtained at higher concentration after gastro-intestinal digestions (GID) of buffalo ice-cream (BIC). It owns potent vascular effect in counteract the effects of angiotensin II-evoked vasoconstriction and high blood pressure levels. Its effects are mediated by the inhibitory effect on AT1 receptor leading to a downregulation of p-ERK½/Rac1-GTP and consequent reduction of oxidative stress. Conclusions: These results strongly candidate PG1, as a novel bioactive peptide for the prevention and management of hypertension, thus expanding the armamentarium of preventive strategies aimed at reducing the incidence and progression of hypertension and its related cardiovascular complications.

ACS Style

Albino Carrizzo; Manuela Basilicata; Giacomo Pepe; Kasper Sørensen; Michele Ciccarelli; Veronica Sarno; Antonio Damato; Eleonora Venturini; Anna Borrelli; Simona Musella; Mario Abate; Paola Pietro; Carmine Ostacolo; Pietro Campiglia; Carmine Vecchione. A Novel Vasoactive Peptide “PG1” from Buffalo Ice-Cream Protects from Angiotensin-Evoked High Blood Pressure. Antioxidants 2021, 10, 441 .

AMA Style

Albino Carrizzo, Manuela Basilicata, Giacomo Pepe, Kasper Sørensen, Michele Ciccarelli, Veronica Sarno, Antonio Damato, Eleonora Venturini, Anna Borrelli, Simona Musella, Mario Abate, Paola Pietro, Carmine Ostacolo, Pietro Campiglia, Carmine Vecchione. A Novel Vasoactive Peptide “PG1” from Buffalo Ice-Cream Protects from Angiotensin-Evoked High Blood Pressure. Antioxidants. 2021; 10 (3):441.

Chicago/Turabian Style

Albino Carrizzo; Manuela Basilicata; Giacomo Pepe; Kasper Sørensen; Michele Ciccarelli; Veronica Sarno; Antonio Damato; Eleonora Venturini; Anna Borrelli; Simona Musella; Mario Abate; Paola Pietro; Carmine Ostacolo; Pietro Campiglia; Carmine Vecchione. 2021. "A Novel Vasoactive Peptide “PG1” from Buffalo Ice-Cream Protects from Angiotensin-Evoked High Blood Pressure." Antioxidants 10, no. 3: 441.